Loading...
Loading...
IMRA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 3.3M |
| Operating I/L | 31.7M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.5M |
| Pretax | 32.3M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | 32.3M |
IMARA Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing therapeutics for rare genetic disorders of hemoglobin. The company's lead product candidate, IMR-687, is an oral and once-a-day therapeutic currently in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. Additionally, IMARA Inc. is developing IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.
